{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:01:40Z","timestamp":1793142100288,"version":"4.5.0"},"reference-count":57,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Aust N Z J Psychiatry"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Psilocybin, a classical psychedelic, has been rescheduled for use in psilocybin-assisted psychotherapy for treatment-resistant depression in Australia. While evidence for its use is promising, understanding the associated risks is crucial. Accordingly, this review aims to collate adverse event data from psilocybin-assisted psychotherapy clinical trials and evaluate its definition, way of measurement and reporting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A systematic method was employed to identify clinical trials related to the use of psilocybin-assisted psychotherapy in clinical populations that reported on adverse events. The quality assessment focused on relevant criteria related to adverse event definition, monitoring and reporting methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 24 articles were included. The studies reported heterogeneous psilocybin doses, study designs and indications. Physical and psychological adverse events during and after psilocybin sessions were examined, revealing variations in measuring, reporting methods and occurrences. The most common adverse events during and after sessions included elevated blood pressure, headaches, nausea, vomiting, fatigue and anxiety. In addition, both suicidal ideation and behaviour were observed infrequently and mainly in participants with a history of suicidal ideation or suicide attempt(s).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The review highlights the need to standardise the defintion of an adverse event, including how they are measured and reported, in psychedelic clinical trials to ensure consistent reporting across studies. In addition, screening participants for suicidality history and ongoing monitoring remains important, given the potential risk identified in the literature. However, based on the available data, the safety of psilocybin-assisted psychotherapy is generally supported, and no deaths were attributed to psilocybin. Nevertheless, cautious optimism is needed due to the preliminary nature and heterogeneity of the safety data.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/00048674241289024","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T05:23:33Z","timestamp":1734067413000},"page":"128-151","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":22,"title":["The safety of psilocybin-assisted psychotherapy: A systematic review"],"prefix":"10.1177","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7683-062X","authenticated-orcid":false,"given":"Rosana R","family":"Freitas","sequence":"first","affiliation":[{"name":"School of Medicine and Psychology, College of Health and Medicine, The Australian National University, Canberra, ACT, Australia"},{"name":"Monarch Research Institute, Monarch Mental Health Group, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathia S","family":"Gotsis","sequence":"additional","affiliation":[{"name":"School of Medicine and Psychology, College of Health and Medicine, The Australian National University, Canberra, ACT, Australia"},{"name":"Monarch Research Institute, Monarch Mental Health Group, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T","family":"Gallo","sequence":"additional","affiliation":[{"name":"School of Medicine and Psychology, College of Health and Medicine, The Australian National University, Canberra, ACT, Australia"},{"name":"Monarch Research Institute, Monarch Mental Health Group, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette M","family":"Fitzgibbon","sequence":"additional","affiliation":[{"name":"School of Medicine and Psychology, College of Health and Medicine, The Australian National University, Canberra, ACT, Australia"},{"name":"Monarch Research Institute, Monarch Mental Health Group, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil W","family":"Bailey","sequence":"additional","affiliation":[{"name":"School of Medicine and Psychology, College of Health and Medicine, The Australian National University, Canberra, ACT, Australia"},{"name":"Monarch Research Institute, Monarch Mental Health Group, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4217-8096","authenticated-orcid":false,"given":"Paul B","family":"Fitzgerald","sequence":"additional","affiliation":[{"name":"School of Medicine and Psychology, College of Health and Medicine, The Australian National University, Canberra, ACT, Australia"},{"name":"Monarch Research Institute, Monarch Mental Health Group, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,12,13]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.12.044"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119897615"},{"key":"e_1_3_2_4_1","article-title":"Eliciting adverse effects data from participants in clinical trials","volume":"1","author":"Allen EN","year":"2018","unstructured":"Allen EN, Chandler CI, Mandimika N, et al. (2018) Eliciting adverse effects data from participants in clinical trials. Cochrane Database of Systematic Reviews 1: MR000039.","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100538"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116678781"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114565144"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.2096"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811221116926"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116662634"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(16)30065-7"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4771-x"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032994"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/jox12010004"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.3285"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-979351"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264927"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113612"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293349"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.8b00186"},{"key":"e_1_3_2_21_1","article-title":"Potential therapeutic effects of psilocybin: A systematic review","volume":"14","author":"Goel DB","year":"2022","unstructured":"Goel DB, Zilate S (2022) Potential therapeutic effects of psilocybin: A systematic review. Cureus 14: e30214.","journal-title":"Cureus"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206443"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01648-7"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675513"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.116"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211073759"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0149-7634(82)90029-X"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109610"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2022.2044096"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114548296"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-017-0542-y"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.05.012"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280231205645"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811221099650"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2023.06.006"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00877-y"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26102948"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1040217"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2016_472"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n1110"},{"key":"e_1_3_2_41_1","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 372: n71.","journal-title":"BMJ"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02455-9"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2023.07.011"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.14530"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00974"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119855974"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675512"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-020-00962-y"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211069100"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2023.03.031"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115349"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231154852"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2022.2047929"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/sltb.12084"},{"key":"e_1_3_2_56_1","volume-title":"Methods Guide for Effectiveness and Comparative Effectiveness Reviews","author":"Viswanathan M","year":"2008","unstructured":"Viswanathan M, Ansari MT, Berkman ND, et al.; AHRQ Methods for Effective Health Care (2008) Assessing the risk of bias of individual studies in systematic reviews of Health Care Interventions. In: Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ)."},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101809"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.1c00024"}],"container-title":["Australian &amp; New Zealand Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00048674241289024","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00048674241289024","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00048674241289024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:57:51Z","timestamp":1777373871000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00048674241289024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1177\/00048674241289024"],"URL":"https:\/\/doi.org\/10.1177\/00048674241289024","relation":{},"ISSN":["0004-8674","1440-1614"],"issn-type":[{"value":"0004-8674","type":"print"},{"value":"1440-1614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,13]]}}}